New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 120mg;   - tablet - 120 mg - active: fexofenadine hydrochloride 120mg   excipient: carmellose colloidal silicon dioxide ferric oxide, pink hypromellose e-15 hypromellose e-5 iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose povidone pregelatinised maize starch titanium dioxide - the treatment of seasonal allergic rhinitis in adults and children 12 years of age

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 60mg;   - tablet - 60 mg - active: fexofenadine hydrochloride 60mg   excipient: colloidal silicon dioxide croscarmellose sodium ferric oxide, pink hypromellose e-15 hypromellose e-5 iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose povidone pregelatinised maize starch titanium dioxide - the treatment of seasonal allergic rhinitis in adults and children 12 years of age

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 180mg - film coated tablet - 180 mg - active: fexofenadine hydrochloride 180mg excipient: colloidal silicon dioxide croscarmellose sodium ferric oxide, pink hypromellose e-15 hypromellose e-5 iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose povidone pregelatinised maize starch titanium dioxide - relief of symptoms associated with seasonal allergic rhinitis in adults and children from 12 years of age.

United States - English - NLM (National Library of Medicine)

nanowell korea inc - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o), silicon dioxide (unii: etj7z6xbu4) (silicon dioxide - unii:etj7z6xbu4), glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - colloidal oat flour - unknown - colloidal oat flour food-plant active 0.0 - active constituent

Malta - English - Medicines Authority

elpen pharmaceutical co. inc. 95 marathonos ave., 190 09 pikermi, attica, greece - amoxicillin, clavulanic acid - film-coated tablet - amoxicillin 500 mg clavulanic acid 125 mg - antibacterials for systemic use

Malta - English - Medicines Authority

elpen pharmaceutical co. inc. 95 marathonos ave., 190 09 pikermi, attica, greece - amoxicillin, clavulanic acid - powder for oral suspension - amoxicillin 250 mg/5ml clavulanic acid 62.5 mg/5ml - antibacterials for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - ibuprofen 200mg; ibuprofen 200mg - film coated tablet - 200 mg - active: ibuprofen 200mg excipient: colloidal silicon dioxide hypromellose e-15 magnesium stearate maize starch propylene glycol purified talc purified water sodium laurilsulfate titanium dioxide active: ibuprofen 200mg excipient: colloidal silicon dioxide hypromellose e-15 magnesium stearate maize starch methyl hydroxybenzoate propyl hydroxybenzoate propylene glycol purified talc purified water sodium laurilsulfate titanium dioxide - ibugesic tablets are indicated for analgesic and anti-inflammatory effect in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthropathies. in the treatment of non-articular rheumatic conditions, ibugesic tablets are indicated in periarticular conditions such as frozen shoulder (capsulitis), bursitis, tendonitis, tenosynovitis and low-back pain. ibugesic tablets can also be used in soft-tissue injuries such as sprains and strains. ibugesic tablets are also indicated for its analgesic effect in the relief of mild to moderate pain such as dysmenorrhoea, dental and post-operative pain. ibugesic tablets are also indicated for the relief of neuralgia, migraine, headache, feverishness and for the relief of the symptoms of cold and influenza.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml; potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml; potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml - powder for oral suspension - 250 mg/5ml - active: amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.